ArticleBMC cancer2025
AHSA1 as a prognostic biomarker and potential immunotherapeutic target in HNSCC: integrative bulk RNA-seq, scRNA-seq analyses and experimental validation.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHeat shock 90 kDa protein ATPase homolog 1 (AHSA1), a chaperone of heat shock protein 90 (Hsp90), is upregulated in various malignancies, where it promotes the invasion, migration, and proliferation of cancer cells. Nevertheless, the precise function of AHSA1 in head and neck squamous cell carcinoma (HNSCC) has yet to be investigated.
methodsTo comprehensively investigate AHSA1 profiles of expression in HNSCC, various techniques including bioinformatics analysis of public databases and qRT-PCR were utilized. To evaluate AHSA1's clinical significance in HNSCC, survival analysis was performed using Cox regression models and Kaplan-Meier curves. The associations between AHSA1 expression, immune microenvironment characteristics, and drug sensitivity were analyzed through bioinformatics approaches. The cellular localization and potential functions of AHSA1 in HNSCC were further investigated through single-cell RNA sequencing (scRNA-seq) analysis. Ultimately, both in vitro and in vivo experimental techniques were used to examine the biological functions of AHSA1 in HNSCC tumor growth and metastasis.
resultsIn HNSCC, AHSA1 expression was markedly upregulated and showed strong associations with clinicopathological factors such as disease stage, TP53 mutation status, and HPV infection status. Survival analysis identified AHSA1 as an independent prognostic biomarker, with elevated expression correlating with adverse clinical outcomes. Notably, an inverse relationship was observed between AHSA1 levels and tumor-infiltrating immune cell populations. Drug sensitivity analysis revealed enhanced therapeutic responsiveness to multiple chemotherapeutic agents in tumors with high AHSA1 expression. Functional validation experiments demonstrated that AHSA1 silencing suppressed tumor growth in HNSCC mice and significantly suppressed cellular proliferation, migration, and invasive potential.
conclusionIn HNSCC patients, AHSA1 might be a useful biomarker for prognostic evaluation and guidance for immunotherapy. Furthermore, inhibition of AHSA1 could effectively suppress tumor growth, invasion, and migration, underscoring its potential for HNSCC treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.